Veranova celebrates first year as an independent CDMO

1^st June 2023

Today marks an incredible milestone for the team at Veranova as we celebrate our first year as an independent CDMO. To celebrate, we are looking back at our achievements during the transition and taking a look at the exciting developments ahead.

With over 50 years of experience navigating the challenges of the global pharmaceutical industry, Veranova proudly builds upon a strong legacy of innovation from its predecessor entities. Since the acquisition by Altaris Capital Partners, LLC from Johnson Matthey on June 1st, 2022, we have combined our expertise in drug development and manufacturing with newfound agility and flexibility. This unique blend allows us to deliver cutting-edge solutions that transform molecules into life-changing medicines.

In our inaugural year, we have expanded our capabilities and embraced a customer-centric approach. A notable highlight is the completion of a significant expansion of our mid-scale API manufacturing capabilities at our facility in Edinburgh, UK. This $10 million investment equips us with a state-of-the-art, multi-purpose asset capable of handling highly active APIs and intermediates.

The team at Veranova would like to thank our clients for a wonderful year of connection and collaboration. We are excited to continue our growth as a leading CDMO partner and leverage our expertise to help you advance your science.